Epidemiological Trends of Mucormycosis in Europe, Comparison with Other Continents.

Autor: Skiada A; First Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527, Athens, Greece. askiada@yahoo.com., Pavleas I; Intensive Care Unit, Laiko Hospital, 11527, Athens, Greece., Drogari-Apiranthitou M; Fourth Department of Internal Medicine, General University Hospital 'Attikon', National and Kapodistrian University of Athens, 12462, Athens, Greece.
Jazyk: angličtina
Zdroj: Mycopathologia [Mycopathologia] 2024 Nov 20; Vol. 189 (6), pp. 100. Date of Electronic Publication: 2024 Nov 20.
DOI: 10.1007/s11046-024-00907-5
Abstrakt: Mucormycosis is an invasive fungal infection, caused by fungi of the order Mucorales, and it is associated with high morbidity and mortality. The epidemiology of mucormycosis is evolving. The incidence, underlying risk factors, clinical presentation, as well as the responsible mucoralean agents, vary by geographic region. The estimated incidence in developed countries ranges from less than 0.06 to 0.3 cases per 100,000 population per year, while in India, it reaches approximately 14 cases per 100,000 population per year, which is about 80 times higher. In European countries the estimated incidence ranges from less than 0.04 to 0.12 per 100,000 population per year. Diabetes mellitus (DM) is the leading underlying disease globally. In Europe, hematological malignancies are the most common risk factor for mucormycosis, while in Asia diabetes predominates. The rhino-cerebral form of mucormycosis is most commonly seen in patients with DM, whereas pulmonary mucormycosis in patients with hematological malignancies and transplants. The most common species globally is Rhizopus arrhizus, whereas new emerging species only occasionally cause infection in Europe. However, vigilance is required, as they may raise concerns-especially in light of climate change- due to their potential to cause serious infections in both immunocompetent and immunosuppressed individuals.
Competing Interests: Declarations. Conflict of interest: The authors have no relevant financial or non-financial interest to disclose.
(© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: